Skip to main content

Table 3 Follow-up for inflammatory markers

From: Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Outcomes Crude analysis p-value^ Beta coefficient (estimates) (95% CI) p-value$*
Control group Tocilizumab group
Serum iron level follow-up, Median (Q1, Q3) 5.88 (3.70, 10.23) 8.91 (3.98, 13.66) 0.004 0.31 (0.15, 0.47) 0.0002
D-dimer level follow-up (mg/l), Median (Q1, Q3) 3.24 (1.13, 8.51) 4.01 (1.53,14.74) 0.006 2.81 (2.39, 3.24) < 0.0001
Fibrinogen level follow-up (gm/l), Median (Q1, Q3) 6.29 (4.59, 7.85) 5.43 (3.60, 7.30) 0.0003 − 0.18 (− 0.28, − 0.08) 0.0002
CRP level follow-up (mg/l), Median (Q1, Q3) 164.0 (84.0, 261.0) 187.0 (93.0, 302.0) 0.14 0.11 (− 0.05, 0.27) 0.18
Procalcitonin level follow-up (ng/ml), Median (Q1, Q3) 0.46 (0.13, 1.73) 0.55 (0.15, 3.32) 0.09 − 0.37 (− 1.77, 1.03) 0.60
  1. ^Wilcoxon rank sum test is used to calculate the p-value
  2. $* Multivariate Logistic regression is used after adjusting for patient’s age, SOFA score, PaO2/FiO2 ratio baseline and systemic corticosteroids during ICU stay to calculate estimates and p-value